Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.

@article{Levine2000EffectOM,
  title={Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.},
  author={T. Barry Levine and Peter J. L. M. Bernink and Avi Caspi and Uri Elkayam and Edward M. Geltman and B. Greenberg and William J. McKenna and Jalal K. Ghali and Thomas D. Giles and Alon T Marmor and Leonardo H Reisin and Susanne Ammon and Elisabet Lindberg},
  journal={Circulation},
  year={2000},
  volume={101 7},
  pages={758-64}
}
BACKGROUND Calcium antagonists have proved disappointing in long-term congestive heart failure (CHF) studies. Mibefradil, a new calcium antagonist that selectively blocks T-type calcium channels, has been shown to be an effective antihypertensive, antianginal, and anti-ischemic agent, and because of its different mechanism of action, it may be beneficial as adjunct therapy in CHF patients. METHODS AND RESULTS This multicenter, randomized, double-blind study compared mibefradil with placebo as… CONTINUE READING
19 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

The management of chronic heart failure

  • J. Cohn
  • N Engl J Med
  • 1996

Effects of the new calcium antagonist mibefradil (Ro 40–5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study

  • A Bakx, E van der Wall, S Braun, H Emanuelsson, A Bruschke, I. Kobrin
  • Am Heart J. 1995;130:748–757
  • 1995

Similar Papers

Loading similar papers…